InsiderTrades.com logo
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing   |   Ad
Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...
I put all the details together for you here — but please hurry. 

RNAC Insider Trading

Insider Ownership Percentage: 57.90%
Insider Buying (Last 12 Months): $2,377,513.02
Insider Selling (Last 12 Months): $2,169,554.63

Cartesian Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cartesian Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cartesian Therapeutics Share Price & Price History

Current Price: $19.02
Price Change: ▼ Price Decrease of -0.25 (-1.30%)
As of 12/20/2024 06:16 PM ET

This chart shows the closing price history over time for RNAC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings   |   Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.

Cartesian Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2024Metin KurtogluCTOSell32,789$16.67$546,592.6351,033View SEC Filing Icon  
11/18/2024Metin KurtogluCTOSell34,400$18.39$632,616.0051,033View SEC Filing Icon  
11/14/2024Metin KurtogluCTOSell25,900$16.44$425,796.0051,033View SEC Filing Icon  
11/14/2024Milos MiljkovicInsiderSell35,000$16.13$564,550.0018,273View SEC Filing Icon  
10/4/2024Timothy A SpringerDirectorBuy80,301$22.58$1,813,196.588,023,766View SEC Filing Icon  
10/2/2024Timothy A SpringerDirectorBuy5,514$17.38$95,833.327,823,559View SEC Filing Icon  
8/12/2024Timothy A SpringerDirectorBuy8,016$12.72$101,963.5211,509View SEC Filing Icon  
3/18/2024Timothy A SpringerDirectorBuy634$18.00$11,412.001,035,780View SEC Filing Icon  
3/14/2024Timothy A SpringerDirectorBuy21,612$16.20$350,114.401,017,228View SEC Filing Icon  
3/11/2024Timothy A SpringerDirectorBuy40$19.50$780.003,213View SEC Filing Icon  
3/8/2024Timothy A SpringerDirectorBuy160$19.80$3,168.003,173View SEC Filing Icon  
2/6/2024Timothy A SpringerDirectorBuy26$19.50$507.002,933View SEC Filing Icon  
1/17/2024Timothy A SpringerDirectorBuy26$20.70$538.202,907View SEC Filing Icon  
See Full Table
Most People Are Dead Wrong.
From Brownstone Research   |   Ad
Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.
I call it my AI Retirement Playbook. I recommend you check it out now.

SEC Filings (Institutional Ownership Changes) for Cartesian Therapeutics (NASDAQ:RNAC)

86.95% of Cartesian Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RNAC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cartesian Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/19/2024Barclays PLC11,611$0.19M0.0%+208.6%0.046%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC135,700$2.19M0.0%+2.1%0.534%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC11,611$0.19M0.0%+208.6%0.046%Search for SEC Filing on Google Icon
11/15/2024State Street Corp157,495$2.54M0.0%+2.5%0.620%Search for SEC Filing on Google Icon
11/15/2024Ikarian Capital LLC52,193$0.84M0.1%-78.5%0.205%Search for SEC Filing on Google Icon
11/13/2024Great Point Partners LLC200,000$3.22M0.9%N/A0.787%Search for SEC Filing on Google Icon
11/13/2024BNP Paribas Financial Markets1,651$27K0.0%+122.5%0.006%Search for SEC Filing on Google Icon
11/13/2024FMR LLC2,851,830$45.97M0.0%+458.3%11.219%Search for SEC Filing on Google Icon
10/23/2024Lake Street Advisors Group LLC15,822$0.26M0.0%-50.0%0.074%Search for SEC Filing on Google Icon
9/16/2024Point72 DIFC Ltd1,725$47K0.0%N/A0.008%Search for SEC Filing on Google Icon
9/16/2024Cubist Systematic Strategies LLC13,010$0.35M0.0%N/A0.061%Search for SEC Filing on Google Icon
9/16/2024Point72 Asia Singapore Pte. Ltd.1,824$49K0.0%N/A0.009%Search for SEC Filing on Google Icon
8/27/2024Logos Global Management LP90,000$2.43M0.2%N/A0.506%Search for SEC Filing on Google Icon
8/15/2024Point72 Asia Singapore Pte. Ltd.1,824$49K0.0%N/A0.009%Search for SEC Filing on Google Icon
8/14/2024Cubist Systematic Strategies LLC13,010$0.35M0.0%N/A0.061%Search for SEC Filing on Google Icon
8/14/2024Point72 DIFC Ltd1,725$47K0.0%N/A0.008%Search for SEC Filing on Google Icon
8/14/2024Marshall Wace LLP30,038$0.81M0.0%N/A0.140%Search for SEC Filing on Google Icon
8/14/2024Logos Global Management LP90,000$2.43M0.2%N/A0.421%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC17,052$0.46M0.0%-96.9%0.096%Search for SEC Filing on Google Icon
8/6/2024Lake Street Advisors Group LLC31,644$0.86M0.0%N/A0.178%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers8,487$0.23M0.0%-93.5%0.048%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp19,916$0.54M0.0%-93.7%0.112%Search for SEC Filing on Google Icon
7/22/2024Hall Laurie J Trustee1,759$48K0.0%-96.7%0.010%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.9,136,635$5.94M0.2%N/A171.098%Search for SEC Filing on Google Icon
5/14/2024American International Group Inc.56,202$37K0.0%N/A1.052%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.6,315,113$4.11M0.0%N/A118.172%Search for SEC Filing on Google Icon
5/7/2024SG Americas Securities LLC47,134$31K0.0%N/A0.883%Search for SEC Filing on Google Icon
5/3/2024Delphi Financial Group Inc.660,852$0.43M0.3%N/A12.261%Search for SEC Filing on Google Icon
5/1/2024BNP Paribas Financial Markets59,125$38K0.0%N/A1.097%Search for SEC Filing on Google Icon
4/23/2024Hall Laurie J Trustee52,775$34K0.0%N/A0.979%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cartesian Therapeutics logo
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Read More on Cartesian Therapeutics

Today's Range

Now: $19.02
Low: $18.73
High: $19.88

50 Day Range

MA: $20.10
Low: $16.62
High: $25.14

52 Week Range

Now: $19.02
Low: $11.66
High: $41.87

Volume

778,468 shs

Average Volume

101,223 shs

Market Capitalization

$483.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Who are the company insiders with the largest holdings of Cartesian Therapeutics?

Cartesian Therapeutics' top insider shareholders include:
  1. Timothy A Springer (Director)
  2. Metin Kurtoglu (CTO)
  3. Milos Miljkovic (Insider)
Learn More about top insider investors at Cartesian Therapeutics.

Who are the major institutional investors of Cartesian Therapeutics?

Cartesian Therapeutics' top institutional investors include:
  1. FMR LLC — 11.22%
  2. Great Point Partners LLC — 0.79%
  3. State Street Corp — 0.62%
  4. Geode Capital Management LLC — 0.53%
  5. Ikarian Capital LLC — 0.21%
  6. Lake Street Advisors Group LLC — 0.07%
Learn More about top institutional investors of Cartesian Therapeutics stock.

Which major investors are selling Cartesian Therapeutics stock?

Within the previous quarter, RNAC stock was sold by these institutional investors:
  1. Ikarian Capital LLC
  2. Lake Street Advisors Group LLC
During the last year, company insiders that have sold Cartesian Therapeutics company stock include:
  1. Timothy A Springer (Director)
  2. Metin Kurtoglu (CTO)
Learn More investors selling Cartesian Therapeutics stock.

Which major investors are buying Cartesian Therapeutics stock?

Within the last quarter, RNAC stock was acquired by institutional investors including:
  1. FMR LLC
  2. Great Point Partners LLC
  3. Barclays PLC
  4. Barclays PLC
  5. State Street Corp
  6. Geode Capital Management LLC
  7. BNP Paribas Financial Markets
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing   |   Ad
Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...
I put all the details together for you here — but please hurry.